drugset / Trial / NCT00191893
Bone Effects of Teriparatide Following Alendronate
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the effect of 24 months of treatment with once daily teriparatide injection (recombinant human PTH \[1-34\]) 20 micrograms on bone histomorphometry and architecture. Patients will include postmenopausal, osteoporotic women who have been treated long term (at least 36 months) with alendronate, as well as postmenopausal, osteoporotic women who have never been treated for osteoporosis.
Timeline
- Start
- 2003-09
- Primary completion
- —
- Completion
- 2006-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Teriparatide | Protein / enzyme biologic | 20 ug | Subcutaneous |